Loading...
•
Jun 30, 2025
Edwards Lifesciences Q2 2025 Earnings Report
Edwards Lifesciences reported strong Q2 2025 results with double-digit revenue growth and raised guidance.
Key Takeaways
The company delivered $1.53B in revenue, driven by solid TAVR and TMTT growth, with EPS of $0.57 and adjusted EPS of $0.67. Net income reached $333M, and guidance for full-year sales and EPS was raised.
Revenue grew to $1.53B, up from $1.37B last year
TAVR sales reached $1.13B, driven by SAPIEN technology adoption
TMTT sales surged to $134.5M, fueled by PASCAL and EVOQUE
Full-year sales and EPS guidance raised due to strong performance
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Edwards Lifesciences raised its full-year sales and EPS guidance, citing strong TAVR and TMTT performance.
Positive Outlook
- Full-year sales growth guidance raised to 9-10%
- TAVR sales guidance increased to $4.3B-$4.5B
- Adjusted EPS expected at high end of $2.40-$2.50
- Q3 sales projected between $1.46B-$1.54B
- Q3 adjusted EPS projected $0.54-$0.60
Challenges Ahead
- Gross profit margin declined year-over-year due to higher manufacturing costs
- Increased SG&A spending expected in second half
- Foreign exchange impacts on profitability
- Higher operating expenses anticipated due to JenaValve spending
- Impairment loss of $47.1M recorded in Q2
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...